In a recent discussion on CNBC, Jim Cramer has shifted his perspective on technology stocks, particularly those related to artificial intelligence (AI) and data center companies. Cramer observed a worrying trend of increasing insider selling and borrowing activity in these sectors, prompting him to reassess his previously bullish outlook. Notably, he described the period of “magical investing,” where buying stocks linked to data centers guaranteed profits, as now concluded. Cramer had once predicted that 2025 would be a pivotal year for data center investments, but he has now amended his stance, declaring this phase “over” and “dead.”
As AI stocks experience a decline in momentum, Cramer noted that investors are exploring alternatives in non-tech sectors for diversification. During his program, he addressed a caller’s concerns regarding the off-price retailer TJX Companies Inc. (NYSE:TJX). Cramer advised the caller to maintain their position in TJX, emphasizing the company’s resilience in challenging market conditions. “TJX is really strong,” he asserted. “It works in a bad market, and right now we got a bad one. I say own TJX, not sell it.” Currently, TJX boasts a dividend yield of approximately 1.2%, with the stock showing a notable rise of 21% year-to-date.
Alongside TJX, Cramer highlighted midstream energy firm Energy Transfer LP (NYSE:ET) as a compelling investment due to its high dividend yield of around 7.8%. Despite a 13% decline in its stock value this year and disappointing Q3 earnings results, Cramer remains optimistic. “Don’t wonder, buy,” he encouraged viewers regarding the stock, identifying it as a promising opportunity in the current market landscape.
Additionally, Cramer discussed consumer packaged goods companies like Procter & Gamble (NYSE:PG) as solid choices for investors navigating a down market. He praised Procter for its innovation and competitive strategies, noting its dividend yield of 2.85% and its ability to achieve efficiency gains through scale and science.
Cramer also expressed a positive outlook for Johnson & Johnson (NYSE:JNJ), particularly following the FDA’s approval of its Caplyta drug for treating major depressive disorder in adults, which he sees as a crucial development for the company.
As investors remain cautious and seek stability in their portfolios, Cramer’s recommendations reflect a broader trend toward more conservative investment strategies in uncertain financial times.
